anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ABSTRACT OF THE DISCLOSURE      New compounds having the general formula (I), as well as their pharmacologically acceptable addition salts with acids, are disclosed.  In the formula (I), either (Ia) R11 stands for a hydrogen atom in the .beta. position, whereas R12 and R13-each represent a hydrogen atom, or (Ib) R11 stands for a hydrogen atom in the .beta. position, whereas R12 and R13 together represent a second bond, or (Ic) R11 and R12 together represent a second bond, whereas R13 stands for a hydrogen atom, or (Id) R11 stands for a hydrogen atom in the .alpha. position, whereas R12 and R13 together represent a second bond.  In all cases (Ia, Ib, Ic, or Id), X stands for an oxygen atom, the hydroxymino grouping > N ? OH or two hydrogen atoms, R1 stands for a hydrogen atom or a methyl group; R2 stands for a hydroxy group, a C1-C10 alkoxy or C1-C10 acyloxy group, whereas R3 and R4 have the usual meanings for competitive pregesterone antagonists, given in the description.  Also disclosed are processes for producing these new compounds, pharmaceutical compositions containing these compounds, their use to produce medicaments and new intermediate products required for the process.  These new compounds have a strong affinity for the gestagen receptor, as well as strong antigestagenous, antiglucorticoidal, antimineralcorticoidal and antiandrogenous properties.
Musical hallucinations (MH) are the subjective experience of hearing music when none is played. They are a rare, understudied area of psychiatry. MH are more common in women and older age and have several underlying aetiologies and predisposing factors such as hearing impairment, mental illness and certain medications. There are no consensus guidelines on treatment; thus, current treatment has two broad approaches: (1) the removal of potential inciting factors (e.g. optimising hearing aids, medications) or (2) pharmacotherapy (antipsychotics, antidepressants, mood stabilisers and cognitive enhancers). This paper presents a case series of patients presenting with MH to a psychiatry of old age service in Dublin City and reviews the current literature of MH. Older age, female gender and hearing impairment are known risk factors for MH. Our findings concurred with the literature-two of three patients were female, and two of three patients suffered from hearing impairment. As this was a psychiatry of old age service, all patients were elderly. One case had a swift resolution of symptoms with a combination of an antipsychotic and antidepressant. The other two cases had limited responses to treatment despite optimising their hearing aids and trials of a number of medications at therapeutic levels. Further research into MH is needed to establish a treatment that is evidence based and symptom focused.
The control group (n=23) will not receive lower extremity posterior muscle myofascial therapy. They will continue the routine exercise program.
FIELD: veterinary. SUBSTANCE: method involves preparing of preparation of natural sexual pheromones from tissues and excreta of adult boar. Source of biological material is testicles, submaxillary glands and urine of matured boars which are homogenized at the ratio 1:(1-2):(2-2.3). Then potassium iodide (2-2.5% of total mixture mass) is added to the prepared mixture and incubated for 6-7 h at 4-5 C. Then mixture is mixed with 15-20% trichloroacetic acid at the ratio 10:1-1.5 following by centrifugation up to separation for two fractions. Then supernatant liquid is distilled with steam. EFFECT: improved method of pheromone preparing. 3 tbl
A starch-based Amygel for the controlled delivery of a biologically active agent is described. The Amygel comprises a dispersed phase, and a dispersion medium consisting substantially of an organic solvent. The dispersed phase includes a polymeric network comprising a hydrolyzable polymeric substance derived from starch, and a cross-linker. In various embodiments, the polymeric starch-derived network includes amylose, amylopectin, soluble starch or a combination thereof. The cross-linker is a molecule having at least two carboxyl moieties. The hyrogel is biocompatible and biodegradable, and suitable for loading with biologically active agents including small molecule therapeutics, macromolecules such as proteins, polysaccharides and nucleic acids. Upon administration to a host animal, the Amygel biodegrades, releasing as degradation products only naturally-occurring sugar molecules that are non-toxic and non-immunogenic to the host.
Such designs are widely used in efficiently informing decisions to proceed to Phase III clinical trials. This trial design is appropriate when the effect of the placebo arm can reasonably be estimated (weight loss is likely to be close to 0), and the toxicity of the treatment is minimal (no toxicity is anticipated related to weight loss).18 Therefore, this will be a single arm 6-month study of 40 participants (20 at each site). All participants will be assigned to the weight loss intervention.
The invention discloses a compound natural polysaccharide with an effect of reducing blood fat. The compound natural polysaccharide composition contains the following components in parts by weight: 1-80 parts of konjac glucomannan, 1-80 parts of carrageenin, 0-60 parts of guar gum, and 0-30 parts of xanthan gum. The raw materials are all natural polysaccharides, so that the compound natural polysaccharide disclosed by the invention is safe in use; the viscosity value of the compound natural polysaccharide gum is relatively high, and the viscosity is basically not changed over time. The compound natural polysaccharide gum is expanded in stomach due to high water absorption so as to improve the satiety, delay gastric emptying and reduce the intake of food. The compound natural polysaccharide gum can influence the absorption of cholesterol in intestinal tracts, reduce the content of lipid compounds and cholesterol in blood and reduce the storage of body fat. The compound natural polysaccharide disclosed by the invention is wider in application range, and is suitable for use by Muslim and Judaism regions and vegetarians.
SAFETY-A is a brief, family centered, cognitive-behavioral approach to therapeutic risk assessment and safety planning that can be delivered via school-based providers. The intervention is delivered in one session during which the youth at risk for suicidal behavior works with the provider to identify strengths, supports, understand emotional antecedents and warning signs, identify alternative coping behaviors and thoughts, and ways to keep the environment safe. Youth and families receive follow-up contacts after the SAFETY-A session. The primary focus is on the therapeutic mechanisms of hope, reduced intensity of suicidal urges, increased confidence in ability to keep safe. Adaptation of SAFETY-A for Schools will target mechanisms that are presumed to drive disparities in mental health service use among Asian American and Latinx youth: (1) trust in mental health services, (2) internalized stigma, and (3) comfort communicating distress.
The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.
Subjects will be randomized to sequence BA, where A represents fasted state and B represents fed state. Subjects will be orally administered a single dose of GW273225 50 mg immediately after a high fat breakfast in dosing period 1. The subjects will receive a single oral dose of GW273225 50 mg in the fasted state in dosing period 2. There will be at least 21 days between doses for the fed and fasted treatment phases of the study.
The lymphatic system plays a vital role in the regulation of tissue fluid balance and the immune response to inflammation or infection. The effects of lymphatic endothelial cells (LECs) on the regulation of neutrophil migration have not been well-studied. In three murine models: imiquimod-induced skin inflammation, Staphylococcus aureus-induced skin infection, and ligature-induced periodontitis, we show that numerous neutrophils migrate from inflamed or infected tissues to the draining lymph nodes via lymphatic vessels. Moreover, inflamed or infected tissues express a high level of interleukin (IL)-17A and tumor necrosis factor (TNF)-α, simultaneously with a significant increase in the release of neutrophil attractors, including CXCL1, CXCL2, CXCL3, and CXCL5. Importantly, in vitro stimulation of LECs with IL-17A plus TNF-α synergistically promoted these chemokine secretions. Mechanistically, tetra-transmembrane protein CMTM4 directly binds to IL-17RC in LECs. IL-17A plus TNF-α stimulates CXC chemokine secretion by promoting nuclear factor-kappa B signaling. In contrast, knockdown of CMTM4 abrogates IL-17A plus TNF-α activated nuclear factor-kappa B signaling pathways. Lastly, the local administration of adeno-associated virus for CMTM4 in Prox1-CreERT2 mice, mediating LEC-specific overexpression of CMTM4, promotes the drainage of neutrophils by LECs and alleviates immune pathological responses. Thus, our findings reveal the vital role of LECs-mediated neutrophil attraction and clearance at sites of inflammation or infection.
The invention discloses a Chinese medicine sit bathing preparation for treating hemorrhoids sore. Chinese medicine considers that hemorrhoids sore is caused by channel blocking and qi and blood stagnating due to damp heat stagnation. The Chinese medicine sitting bathing preparation selects Chinese medicines of radix scutellariae, coptis chinensis, cortex ailanthi, fructus forsythiae, dandelion, ligusticum wallichii, myrrh, trogopterus dung, semen strychni and acacia catechu which having the effects of cleaning heat, drying damp, promoting blood circulation, removing blood stasis and relieving swelling and pain to prepare the sitting bathing preparation. First fumigation is performed, and then sitting bathing is performed. The Chinese medicine sitting bathing preparation for treating the hemorrhoids sore is proved by clinical experiments of our hospital that the curative rate of anal selling and pain respectively reaches 89.6% and 91.3%. The curative effects of the anal selling and pain are respectively better than a comparison group, curative cost is low, and toxic and side effects do not exist.
People with visual impairment face significant material challenges to access and inclusion in South Africa. These are in large part rooted in and supported by prejudiced assumptions about the needs, nature and capabilities of this group. The cultural and psychological face of oppression needs to be attended to. To this end, this viewpoint brings together the work of three visually impaired scholars in three key areas pertaining to the promotion of the inclusion and citizenship of visually impaired persons in South Africa. These areas are education; rehabilitation; and social inclusion and visibility. This work argues that undoing lifelong exclusion requires examining how disablism is embedded in the very fabric of our societies and operational at various levels: material, administrative, cultural and relational.
INTRODUCTION: Current risk score models for predicting mortality in infective endocarditis (IE) include data often unavailable in registries, limiting their use for confounding adjustment in population-based research.
METHODS: This study assessed the Danish Comorbidity Index for Acute Myocardial Infarction (DANCAMI) for its ability to predict 30-day, 1-year, and 5-year mortality in IE patients, compared to the Charlson Comorbidity Index (CCI) and Elixhauser Comorbidity Index (ECI). The study included all adult Danish patients with first-time IE from 1995 to 2021. The area under the receiver operating characteristic curve (AUC) was estimated using logistic regression to measure discriminatory performance for all-cause and cardiovascular mortality at the specified time intervals. A baseline model included age and sex, while extended models incorporated continuous comorbidity scores.
RESULTS: We identified 8966 patients with IE. Mortality rates were 12% at 30 days, 26% at 1 year, and 36% at 5 years. For all-cause mortality, AUCs for the baseline versus DANCAMI models were 0.64 vs. 0.69 at 30 days, 0.66 vs. 0.73 at 1 year, and 0.72 vs. 0.79 at 5 years. For cardiovascular mortality, AUCs for baseline versus DANCAMI models were 0.67 vs. 0.69 at 30 days, 0.67 vs. 0.69 at 1 year, and 0.70 vs. 0.71 at 5 years. CCI and ECI demonstrated comparable AUCs to the DANCAMI model.
CONCLUSION: DANCAMI improved discrimination of short- and long-term mortality in IE patients and may be used for confounder adjustment similarly to CCI and ECI.
PROBLEM TO BE SOLVED: To obtain a leukemia medicine containing 9-cis-retinoic acid α-tocopherol ester, little in side effects, and effective at a low dose. SOLUTION: This leukemia medicine contains 9-cis-retinoic acid α-tocopherol ester of the formula as an active ingredient. The leukemia medicine contains the compound of the formula and 1α,25-dihydroxyvitamin D3 , or the compound of the formula and 9-cis-retinoic acid as active ingredients. The compound of the formula itself has an activity to inhibit the proliferation of leukemic calls and an action an inducing the differentiation of the leukemia cells, but the simultaneous use of the vitamin D3 or the 9-cis-retinoic acid exhibits synergistic effects. The compound of the formula and the 1α,25-dihydroxyvitamin D3 are administered at daily doses of 10-1200mg and 0.005-5μg, respectively, per an adult, and the compound of the formula and the 9-cis-retinoic acid are also administered at daily doses of 10-1200mg and 1-80mg, respectively, per an adult.  The leukemia medicine is especially effective for acute promyelocytic leukemia and lymphoma.
Beta-blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia. Nonselective beta-blockers may potentiate insulin-induced hypoglycemia and delay recovery of serum glucose levels. Because of its beta1-selectivity, this is less likely with bisoprolol fumarate. However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities. Also, latent diabetes mellitus may become manifest and diabetic patients given thiazides may require adjustment of their insulin dose. Because of the very low dose of hydrochlorothiazide employed, this may be less likely with bisoprolol fumarate and hydrochlorothiazide.
Nasal reconstruction is a challenging practice with the potential for complications. Surgeons can prevent complications through preoperative optimization of patient factors, refinement of intraoperative surgical techniques, and postoperative surgical and nonsurgical wound care. Preoperatively, optimization of modifiable and recognition of nonmodifiable risk factors is paramount. Intraoperatively, meticulous flap design and surgical technique promote healing. In the postoperative setting, attentive wound care, adjuvant therapies, and close follow-up for consideration of additional procedures enhance outcomes. By anticipating potential complications across perioperative settings, surgeons can prevent common complications in nasal reconstruction and more effectively manage those complications that arise.
The invention relates to a method for preparing root of ballon flower into the drug that kills sperm externally. The root of ballon flower can kill sperm externally; therefore, the invention makes it into emulsion or bougie. And the production comprises that: breaking root of ballon flower, immerging in 0.9% normal saline at 100g: 900-1200ml, heating in metal bath at 100Deg. C, taking out, filtering, removing slag, to obtain extractive, and treating extractive into emulsion or bougie. The inventive extractive will not stimulate vaginal mucosa, and affect the vaginal bacterial, without side effect. And it can function long time.
Participants who will be randomized to receive placebo in Stage 1 and will be classified as non-responders (responders" if modified Clinical Global Impression of Severity \[mCGI-S\] score is ≤ 3 at Day 43 and Neuropsychiatric Inventory Clinician (NPI-C)-3 score has decreased by ≥ 25% from baseline. Participants who will not meet these criteria will be considered "non-responders) after Week 6 will be re-randomized to continue receiving AVP-786 matching placebo capsules, orally, BID during Weeks 7 to 12 of the Stage 2 treatment period.
Uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCTs) are rare uterine mesenchymal neoplasms with uncertain biological potential. These tumors, which affect both premenopausal and postmenopausal women, usually have a benign clinical course. Nevertheless, local recurrences and distant metastases have been described. By analyzing 511 cases retrieved from individual reports and cases series, we provide here the most comprehensive overview of UTROSCT cases available in the literature, supplemented by two new cases of UTROSCTs. Case 1 was an asymptomatic 31-year-old woman who underwent a laparoscopic resection of a presumed leiomyoma. Case 2 was a 58-year-old postmenopausal woman with abnormal vaginal bleeding who underwent an outpatient hysteroscopic biopsy of a suspicious endometrial area. In both cases, immunohistochemical positivity for Calretinin and Inhibin was noted, typical for a sex cord differentiation. In both cases, total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed. In light of the available literature, no pathognomonic clinical or imaging finding can be attributed to UTROSCT. Patients usually present with abnormal uterine bleeding or pelvic discomfort, but 20% of them are asymptomatic. In most cases, a simple hysterectomy appears to be the appropriate treatment, but for women who wish to become pregnant, uterus-preserving approaches should be discussed after excluding risk factors. Age, tumor size, lymphovascular space invasion, nuclear atypia, and cervical involvement are not reliable prognostic factors in UTROSCT. The current research suggests that aggressive cases (with extrauterine spread or recurrence) can be identified based on a distinct genetic and immunohistochemical phenotype. For instance, UTROSCTs characterized by GREB1::NCOA1-3 fusions and PD-L1 molecule expression appear to be predisposed to more aggressive behaviors and recurrence, with GREB1::NCOA2 being the most common gene fusion in recurrent tumors. Hence, redefining the criteria for UTROSCTs may allow a better selection of women suitable for fertility-sparing treatments or requiring more aggressive treatments in the future.
Thiotepa and/or its active metabolites may be excreted in part via skin patients receiving high-dose therapy. Treatment with thiotepa may cause skin discoloration, pruritus, blistering, desquamation, and peeling that may be more severe in the groin, axillae, skin folds, in the neck area, and under dressings. Instruct patients to shower or bathe with water at least twice daily through 48 hours after administration of thiotepa. Change occlusive dressing and clean the covered skin at least twice daily through 48 hours after administration of thiotepa. Change bed sheets daily during treatment.

Skin reactions associated with accidental exposure to thiotepa may also occur. Wash the skin thoroughly with soap and water in case thiotepa solution contacts the skin. Flush mucous membranes in case of thiotepa contact with mucous membranes.
PURPOSE:To facilitate the production of the subject material by incorporating a calcium compd. or phosphoric acid compd. into a hydroxy apatite powder slurry, molding and calcining, thereby phase-splitting calcium oxide or calcium triphosphate by a solid-phase reaction. CONSTITUTION:The slurry for wet molding contg. the hydroxy apatite powder (preferably 1.67Ca/P ratio) and water-soluble calcium or phosphoric acid compd. is prepd. The solid-phase reaction takes place between the water-soluble calcium or phosphoric acid compd. and the apatite contained in the slurry and the calcium oxide or calcium triphosphate is phase-split in the process of calcination if the slurry is wet molded and the molding is calcined at 900 to 1300 deg.C under normal pressure. While this phase-splitting quantity depends on the amt. of the water-soluble calcium or phosphoric acid compd. to be added, the quantity varies more or less with calcination conditions as well and is, therefore, adequantely set. The porous biomaterial is obtd. if hydrogen peroxide, expendable material, etc., are previously incorporated into the slurry.
Each participant will receive a series of nine active laser or sham treatments on a M-W-F schedule over the three week treatment period. Participants in the laser treatment group will be treated at 42 watts for up to 60 seconds at tender spots in the spine or extremities. Total treatment time is not to exceed 30 minutes.
1388198 Antibiotic FR-1923 FUJISAWA PHARMACEUTICAL CO Ltd 18 Aug 1972 [31 Aug 1971] 38586/72 Heading C2A A new antibiotic designated "FR-1923" is isolated as a white, crystalline, amphoteric solid from aerobic cultures of an organism of the species Nocardia uniformis in a nutrient medium containing sources of assimilable carbon, nitrogen and inorganic salts. The preferred organism is Nocardia uniformis var. tsuyamanensis ATCC 21806. Isolation is by conventional procedures from the filtered broth. The antibiotic forms a sodium salt (also claimed) which may readily be converted to the free compound, e.g. by treatment with an acid. Pharmaceutical compositions in conventional forms for oral, parenteral and local application may be produced comprising the antibiotic and/or its salts and conventional pharmaceutical carriers and excipients.
Cosmetic active substance preparation with a radical protection factor comprises: a) 0.1 to 10 wt. % of a product obtained by extraction of the bark of Quebracho blanco and subsequent enzymatic hydrolysis, containing at least 90 percent by weight of proanthocyanidine oligomers and up to 10 percent by weight of gallic acid and present as a microcapsule with a concentration of the extraction product of 2 wt %; (b) from 0.1 to 10 wt. % of an extract of silkworm obtained by extraction, containing the peptide cecropine, amino acids and a vitamin mix; (c) 0.1 to 5 wt. % of a non-ionic, cationic or anionic hydrogel or mixture of hydrogels; (d) 0.1 up to 30 wt. % of at least one phospholipid and (e) water. The radical protection factor is in the range 100 to 3500 X 1014 radicals/ mg preparation.
PURPOSE: Provided are Polygonatum odoratum Druce var. Pluriflorum Ohwi extract having skin whitening effect and a skin whitening cosmetic composition containing the same as an active ingredient. CONSTITUTION: Polygonatum odoratum Druce var. Pluriflorum Ohwi extract is obtained by extracting one of Polygonatum odoratum(Mill). Druce var. pluriflorum(Miq.) ohwi, Polygonatum involucratum, Polygonatum inflatum Kom, Polygonatum robustum nakai, Polygonatum lasianthum var. coreanum nakai and Polygonatum falcatum A. gray, with one of water, 1,3-butyleneglycol, propyleneglycol and ethanol. A skin whitening cosmetic composition contains based on the total weight of the composition, 1.0-15.0 wt.% of the extract.